Your Health, We Care
Adults and Pediatric Patients 2 Years and Older
Coadministration of Entrectinib with a strong or moderate CYP3A inhibitor increases entrectinib plasma concentrations, which could increase the frequency or severity of adverse reactions. Avoid coadministration of strong or moderate CYP3A inhibitors with Entrectinib. If coadministration is unavoidable, reduce the Entrectinib dose.
Pediatric Patients less than 2 Years
Avoid coadministration of Entrectinib with moderate or strong CYP3A inhibitors.
Avoid grapefruit products during treatment with Entrectinib, as they contain inhibitors of CYP3A.
Coadministration of Entrectinib with a strong or moderate CYP3A inducer decreases entrectinib plasma concentrations, which may reduce Entrectinib efficacy. Avoid coadministration of strong and moderate CYP3A inducers with Entrectinib.
QTc interval prolongation can occur with Entrectinib. Avoid coadministration of Entrectinib with other products with a known potential to prolong QT/QTc interval
from FDA，2024.01
